Search

Displaying results 2581 - 2590 of 10000 in total
  1. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040] … Chronic venous insufficiency is a common condition the western population.

  2. Drug

    Corticorelin ovine triflutate

    go.drugbank.com/drugs/DB09067
    Approved

    It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. … It provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess).

  3. Drug

    Prostaglandin D2

    go.drugbank.com/drugs/DB02056
    Experimental

    The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, ...

    Synonyms: Prostaglandin D2Categories: Prostaglandins D, Prostaglandin D2, antagonists & inhibitors
  4. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections.

  5. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

  6. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

  7. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    to reduce Aβ aggregation and remove Aβ plaques. … Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720]

  8. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.

  9. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

  10. Drug

    Iodine povacrylex

    go.drugbank.com/drugs/DB09537
    Approved

    DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection … It is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions. It is intended for local use only.